FDA clears Hugo robot for general surgery; study tests computer vision for operating room records; robotic pancreatoduodenectomy speeds recovery

An instrument tray lined with a folded cloth, holding a scalpel, toothed forceps and curved scissors laid side by side.

Medtronic said the Food and Drug Administration (FDA) cleared its Hugo robotic-assisted surgery system for general surgery, including cholecystectomy, gastric bypass, hernia repair and appendectomy. A JAMA Surgery study tested computer vision for operating room documentation, an individual patient data meta-analysis tied robotic pancreatoduodenectomy to faster recovery, and a Japanese registry found raised cancer incidence in low-risk branch-duct cysts.

  • FDA Nov 17, 2026
    Medtronic said Nov. 17 that the Food and Drug Administration (FDA) cleared the Hugo robotic-assisted surgery system for all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection, as well as inguinal hernia repair and appendectomy. The company said these procedures account for about 3.5 million U.S. surgeries a year. Hugo's first FDA clearance, in December, covered urologic procedures, according to MedTech Dive, which reported that the company said general surgery is Hugo's highest growth area.
  • AI Nov 18, 2026
    A study published Nov. 18 in JAMA Surgery tested Aimbient's computer vision system, which detects when patients enter and exit the operating room, across 14 operating rooms and one procedure room at Stanford Health Care over eight months. With blinded human video review as the ground truth, there was no statistically significant difference in accuracy between automated timestamps and manual documentation, according to the company. The company said human accuracy degraded during overnight shifts and long transplant cases. The study measured documentation accuracy, not patient outcomes.
  • Research Nov 17, 2026
    An individual patient data meta-analysis of four randomized trials at 25 experienced, high-volume centers in seven countries, published Nov. 17 in The Lancet Gastroenterology & Hepatology, found major complications (Clavien-Dindo grade 3 or higher) in 34% of patients after robotic and 32% after open pancreatoduodenectomy (adjusted risk difference -2%, 95% CI -7 to 3; P = .37). Median modified time to functional recovery, the other primary outcome, was nine days versus 12 (adjusted median difference -2, 95% CI -3 to -1; P < .0001). Exploratory subgroup analyses found no heterogeneity by age, obesity or fistula risk.
  • Research Nov 17, 2026
    In a prospective multicenter Japan Pancreas Society registry published Nov. 17 in Annals of Surgery, 1,234 patients with branch-duct intraductal papillary mucinous neoplasms without worrisome features or high-risk stigmata had imaging and laboratory surveillance every six months for up to 5.17 years. Advanced neoplasia developed in 26 patients, 16 of them concomitant pancreatic ductal adenocarcinoma, for a standardized incidence ratio of 4.91 for concomitant cancer. Of 19 patients eligible for extended surveillance intervals, 13 (68%) had a later simulated detection date, and the authors said surveillance based solely on cyst stability may warrant caution.

The weekly innovation roundup for general surgery, published every Sunday for the week before; every item links to its sources. Latest general surgery news · All specialties

Latest news

Tagged general surgery, from the daily briefing

  1. Houston's Memorial Hermann will be the first U.S. hospital to install Johnson & Johnson's Ottava surgical robot
  2. Medtronic's Hugo robot is cleared for gallbladder, hernia and bariatric surgery, widening its use beyond urology
  3. Stanford team reports validation of operating room computer vision for ambient documentation

See all the latest news